Checkpoint inhibitors in treatment of metastatic mucosal melanoma

Mucosal melanoma (MM) is rare and of extremely poor prognosis. Although significant progress has been made in developing new therapies for patients with metastatic melanoma arising from the cutaneous, knowledge about the effects of treatments for patients with MM is limited. In this review we aim to summarize and evaluate related trials.